Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01262547 · ClinicalTrials.gov registry record · Phase 2

A New Micrografting Technique for Vitiligo

A Phase 2 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 2
Development phase
3
Enrollment target

NCT01262547: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.

NCT01262547 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01262547, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 2
Development phase
3 participants
Enrollment target

Study Summary

This study evaluates micrografting using a harvesting and grafting process that has been designed by Momelan Technologies. The overall concept is to harvest several small pieces of skin, each measuring about 1.75 mm in diameter from a normal pigmented area using a commercially available suction blister device, adhere them to a sterile elastomeric substrate and is then place it on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).

Interventions

  • PROCEDURE Dermabrasion
  • DEVICE Dermabrasion-Micrografting

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2011-09
Est. Completion 2013-05
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01262547

The ClinicalTrials.gov registry entry for NCT01262547 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dermabrasion is the first listed.

NCT01262547 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01262547 about?

NCT01262547 is a clinical study titled "A New Micrografting Technique for Vitiligo". This study evaluates micrografting using a harvesting and grafting process that has been designed by Momelan Technologies. The overall concept is to harvest several small pieces of skin, each measuring about 1.75 mm in diameter from a normal pigmented area using a commercially available suction blis...

What is the current status of trial NCT01262547?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2011-09. Estimated completion is 2013-05.

What interventions are being tested in trial NCT01262547?

The interventions under investigation include: Dermabrasion (PROCEDURE), Dermabrasion-Micrografting (DEVICE).

Who is sponsoring clinical trial NCT01262547?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.